|
Product analysis: no product was returned.Conclusion: without the return of the product, no definitive conclusion can be made regarding the clinical observation.Medtronic is submitting this report to comply with fda reporting regulations under 21 cfr parts 4 and 803.This report is based upon information obtained by medtronic, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Medtronic has made reasonable efforts to obtain more complete information and has provided as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.In particular, this report does not constitute an admission by anyone that the product described in this report has any ¿defects¿ or has ¿malfunctioned¿.These words are included in the fda 3500a form and are fixed items for selection created by the fda to categorize the type of event solely for the purpose of regulatory reporting.Medtronic objects to the use of these words and others like them because of the lack of definition and the connotations implied by these terms.This statement should be included with any information or report disclosed to the public under the freedom of information act.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.A good faith effort will be made to obtain the applicable information relevant to the report.If information is provided in the future, a supplemental report will be issued.
|
|
Medtronic received information that 2 days post implant of this 29mm aortic bioprosthetic valve, the patient died.The cause of death was received as cardiogenic shock.It was also reported that a maze procedure and a microaxial heart pump (impella) was implanted concomitantly.It was also reported that one day post operation, the patient required dialysis and the hospital did not have a system that worked with the bypass machine (ecmo).The patient was then sent to the catheter lab for a jugular dialysis catheter placement.One day later, post placement of the jugular catheter, the patient began to bleed and was transported to the icu.The patient was then attempted to be resuscitated via opening the previous surgical wound.It was also reported that the patient reached eventual hemostasis but the support became inadequate and the family elected to withdraw care.It was also reported that the physician stated the medtronic product did not cause or contribute to the patients death.There was no evidence to suggest that the bioprosthetic valve or its function contributed to the patient¿s death.It is unknown whether an autopsy was performed.
|